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Trichilia catigua is a native plant of Brazil; its barks are used by some local pharmaceutical companies to prepare tonic drinks,
suchas Catuama.The present study wasaddressed to evaluatethe eﬀects of T. catigua hydroalcoholic extract inmousenociception
behavioral models, and to evaluate the possible mechanisms involved in its actions. Male Swiss mice were submitted to hot-plate,
writhing and von Frey tests, after oral treatment with T. catigua extract (200mgkg−1, p.o.). The extract displayed antinociceptive
eﬀectinallthreemodels.Forcharacterizationofthemechanismsinvolvedintheantinociceptiveactionoftheextract, thefollowing
pharmacological treatments were done: naloxone (2.5mgkg−1, s.c.), SR141716A (10mgkg−1, i.p.), SCH23390 (15μgkg −1, i.p.),
sulpiride (50mgkg−1, i.p.), prazosin (1mgkg−1, i.p.), bicuculline (1mgkg−1, i.p.) or dl-p-chlorophenylalanine methyl ester
(PCPA, 100mgkg−1, i.p.). In these experiments, the action of T. catigua extract was evaluated in the hot-plate test. The treatment
withSCH23390 completely prevented theantinociceptive eﬀect, whilenaloxonepartiallyprevented it.The possibleinvolvementof
the dopaminergic system in the actions of T. catigua extract was substantiated by data showing the potentiation of apomorphine-
induced hypothermia and by the prevention of haloperidol-induced catalepsy. In conclusion, the antinociceptive eﬀects of
T. catigua extract seem to be mainly associated with the activation of dopaminergic system and, to a lesser extent, through
interaction with opioid pathway.
1.Introduction
Trichilia catigua A. Juss (Meliaceae) is a native plant that
grows abundantly in several regions of Brazil, and it is
popularly known as “catuaba” or “catigua” [1]. This plant
is widely used in folk medicine as a tonic for the treatment
of fatigue, stress, impotence and against deﬁcits of memory,
being also employed as a digestive and purgative substance.
Some pharmaceutical and beverage industries in Brazil use
the barks of this plant to prepare tonic drinks. Commer-
cially available preparations containing T. catigua extracts
often include the association of other plants, with known
stimulant properties. In Brazil, the herbal product Catuama
is made by the association of four hydroalcoholic extracts,
namely T. catigua (28.23%), Paullinia cupana (40.31%),
Ptychopetalum olacoides (28.23%) and Zingiber oﬃcinalis
(3.26%). The product Catuama has been commercialized in
Brazil for more than 20 years, and it is used as a remedy to
relieve physical and mental fatigue, neuromuscular asthenia
and weakness disorders.
Concerning its pharmacological actions, Catuama has
been previously shown to display marked vasorelaxant
actions in vascular preparations obtained from rats, guinea-
pigs and rabbits [2], besides possessing long-lasting (up
to 8h) antinociceptive eﬀects in various thermal (hot-
plate and tail ﬂick) and chemical (acetic acid, formalin
and capsaicin) acute nociception models [3]. The authors
have also evaluated the eﬀects of extracts made from the
plants present in the product Catuama, T. catigua, P. cupana,
P. olacoides and Z. oﬃcinalis,a n dv e r i ﬁ e dt h a tT. catigua
had the higher antinociceptive eﬀect on the acetic acid-
induced nociception [3]. More recently, our group has2 Evidence-Based Complementary and Alternative Medicine
shown that Catuama also produces a prominent reduction
of the mechanical hypersensitivity induced by LPS in rats
[4]. Additional pre-clinical studies have shown a relaxant
action for Catuama in corpus cavernosum strips from
rabbits [5], this eﬀect was correlated with the presence
of P. cupana and T. catigua extracts. Catuama has also
been found able to both revert and prevent ventricular
ﬁbrillation in the isolated rabbit heart, and T. catigua extract
is probably the main agent responsible for these actions
[6]. Of interest, our group has provided pharmacological
and biochemical evidence on the potential antidepressant
eﬀects of the product Catuama and also for the T. catigua
hydroalcoholic extract in rodents, by mechanisms primarily
involving the activation of dopaminergic pathways [7, 8].
Following these lines of evidence, the present study was
addressed to further evaluate the eﬀects of the hydroalco-
holic extract from T. catigua barks on the central nervous
system (CNS), by using some behavioral pharmacological
models in rodents. In addition, eﬀorts have also been made
to further investigate the possible mechanisms underly-
ing these eﬀects, by using experimental models of pain
evaluation.
2.Methods
2.1. Drugs and Reagents. Diazepan, imipramine hydrochlo-
ride, dexamethasone, ﬂuoxetine hydrochloride, haloperidol,
indomethacin, naloxone, DL-p-chlorophenylalanine methyl
ester (PCPA), prazosin, SCH23390, morphine, carrageenan
(all from Sigma Chemical Co. St. Louis, MO, USA);sulpiride
(DEG, S˜ ao Paulo, SP, Brazil); dypirone, acetic acid (Merck
AG, Darmstadt, Germany) SR 141716A (Sanoﬁ Aventis, S˜ ao
Paulo, SP, Brazil). All the drugs used in this study, including
theextractofT. catigua,weredissolvedinphosphatebuﬀered
saline(PBS,LaborclinLtd.,Pinhais, PR,Brazil)tothedesired
concentrationjustbeforeuse.Theselecteddoseswerechosen
according to pilot experiments and also on the basis of
literature data [8, 9].
For the preparation of the extract, botanical material of
T. catigua A. Juss (Meliaceae) was classiﬁed by Dr Gerdt
Guenther Hatschback. A sample of the plant was deposited
at the Municipal Botanical Museum of Curitiba, PR, Brazil
(voucher number 65901). The barks of T. catigua were
minced and extracted with ethanol-water in a proportion of
4:1 (w/v), and maintained at 60◦Cf o r4h .T h es o l v e n tw a s
fully evaporated and concentrated.
2.2. Animals. Swiss male mice (25–30g; N = 8–10 per
group) purchased from the Central Biotery of the Federal
University of Pelotas (Brazil), kept in a room controlled for
temperature (22 ± 2◦C) and humidity (60%–80%), under a
12:12h light-dark cycle (lights on at 6:00am), were used.
Animals were kept in groups of 10 per cage (height 16cm,
w i d t h3 4 c m ,l e n g t h4 9 c m ) .T h em i c ew e r ea c c l i m a t i z e d
to the laboratory for at least 1h prior to experiments and
were used only once in each test. For all behavioral tests,
animals were visually and acoustically isolated during the
experimental sessions. All experiments were carried out
between 08:00am and 5:00pm. The Ethics Committee of
the Pontif´ ıcia Universidade Cat´ olica do Rio Grande do Sul
approved all the experimental procedures (protocol number
2304-07/1). All eﬀorts were made to minimize the number
and suﬀering of animals.
2.3. Hot-Plate Test. The hot-plate test was used to measure
the response latencies according to the method described
previously [10]. Brieﬂy, the animals were placed on the
hot-plate apparatus (54 ± 1◦C) to measure the baseline
responsiveness. Subsequently, diﬀerent groups of mice were
treated with the hydroalcoholic extract from T. catigua
(200mgkg−1, p.o.), the positive control drug morphine
(4mgkg−1, s.c.), or PBS solution (10mlkg−1, p.o.). Separate
groups of mice received Fraction 2 (200mgkg−1, i.p.),
Compound 2 or cinchonain IIB (20 and 40mgkg−1, i.p.),
each one isolated from T. catigua hydroalcoholic extract by
column chromatography; the doses employed in our study
were chosen based on pilot studies. The responsiveness of
animals in the hot-plate apparatus was registered between
3 and 6h after treatment; each time point was represented
by one group of mice (n = 10 per group). The results of the
time-course curve were used to determine the schedules of
treatment forthenext experiments. Alatencyperiod (cutoﬀ)
of 30 s was deﬁned as complete analgesia.
In order to evaluate the neurotransmitter systems
involved in the antinociceptive eﬀects of T. catigua
extract, mice were pretreated with naloxone (non-selective
opioid receptor antagonist, 2.5mgkg−1, s.c.); SCH23390
(15μgkg −1, i.p.) and sulpiride (50mgkg−1, i.p.), selective
dopamine D1 and D2 receptor antagonists, respectively;
prazosin (α1-adrenergic receptor antagonist, 1mgkg−1, i.p.),
bicuculline (GABAA receptor antagonist, 1mgkg−1, i.p.),
DL-p-chlorophenylalanine methyl ester (PCPA, serotonin
synthesis inhibitor, 100mgkg−1 i . p . ,4d a y s ,o n c ead a y ) ;o r
SR141716A (cannabinoid receptor antagonist, 10mgkg−1,
i.p.). The drugs were injected immediately after evaluating
the baseline responsiveness, and 10min before the admin-
istration of T. catigua hydroalcoholic extract (200mgkg−1,
p.o.).
2.4. Measurement of Mechanical Hypersensitivity. The
mechanical nociceptive threshold of the hindpaw was
determined as described elsewhere [11]. Through a wire
mesh ﬂoor of a chamber, a series of nine von Frey hair
monoﬁlaments (St¨ oelting, Wood Dale, IL, USA), calibrated
to produce incremental forces of 0.02, 0.04, 0.07, 0.16, 0.4,
0.6, 1.0, 1.4 and 2.0g, were applied to the middle of the
plantarsurface oftherighthindpaw foramaximum of8s, or
until the animal displayed a nocifensive response, consisting
of paw lifting and/or shaking. Testing was initiated with
the 0.6g ﬁlament. In the absence of a clear paw withdrawal
response, increasingly stronger ﬁlaments were presented
consecutively, until one of them was found to elicit such a
response. If the 0.6g ﬁlament elicited a response, ﬁlaments
with decreasing strength were presented until determination
of the ﬁrst one which failed to cause paw withdrawal. Data
was collected using the up-down method [12]t oc a l c u l a t e
the 50% mechanical paw withdrawal threshold (in g).
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were interpreted as indicative of mechanical allodynia. In
our procedure, the basal response was registered 24h before
the test, and only animals responding to 0.6g ± 20% were
selected. The animals were submitted to preventive and
therapeutic treatment regimens. In preventive regimen,
mice were treated with T. catigua extract (200mgkg−1, p.o.),
PBS as the negative control, or dexamethasone (1mgkg−1,
i.p.) as the positive control, followed by intraplantar (i.pl.)
injection of 50μl of carrageenan (300μg) into the right
hindpaw. For the therapeutic treatment, carrageenan
(300μg/50μl/paw i.pl.) was injected into the right hindpaw,
and 1h later, mice received the T. catigua hydroalcoholic
extract (200mgkg−1, p.o.), PBS as the negative control, or
indomethacin (5mgkg−1, i.p.) and morphine (5mgkg−1,
i.p.), as the positive control drugs.
2.5. Abdominal Constrictions Induced by Acetic Acid. The
abdominal constrictions were assessed according to proce-
dures described previously [13]. They comprise a contrac-
tion of the abdominal muscle, together with a stretching
of the hind limbs in response to an i.p. injection of acetic
acid (0.8%). Mice were pretreated with the hydroalcoholic
extract of T. catigua (200mgkg−1, p.o.), 4h before acetic
acid injection. Control animals received a similar volume of
PBS (10mlkg−1, p.o.) or dypirone (150mgkg−1, p.o.), 1h
before the application of acetic acid. After the injection of
the algogenic agent, mice were individually placed into glass
cylindersof20cmdiameter,andtheabdominalconstrictions
were counted cumulatively over a period of 15min.
2.6. Apomorphine-Induced Hypothermia. For this test, the
procedures used were similar to those described previously
[14]. Temperature measurements were performed in a
temperature-controlled room (22 ± 2◦C), between 3:00pm
and 5:00pm. The mouse colonic temperature was recorded
using a commercially available thermometer (Pro-check),
which was dipped in Vaseline and inserted ∼0.5cm into a
gently hand-restrained mouse. After recording their initial
colonictemperature (t =0),diﬀerentgroupsofmicereceived
either T. catigua hydroalcoholic extract (200mgkg−1, p.o.)
orPBS(10mlkg−1,p.o.).Followingtheappropriateintervals
of treatment (4h for the extract and 1h for the PBS-treated
animals); the animals received apomorphine (16mgkg−1,
s.c.) or PBS. Their colonic temperature was recorded 30 and
60min after the last treatment.
2.7. Catalepsy. In order to evaluate the eﬀects of T. catigua
extract on the catalepsy induced by the antipsychotic
haloperidol (a dopaminergic receptor antagonist); diﬀerent
groups of mice were pre-treated with PBS (10mlkg−1, p.o.)
or with T. catigua extract (200mgkg−1, p.o.). Following the
appropriate intervals of time (4h for the extract; 1h for the
control groups), the animals were treated with haloperidol
(4mgkg−1,i.p.)orPBS.Catalepsywasmeasured30minafter
haloperidol injection, by placing the forepaws over a 0.5cm
diameterhorizontalglassbar, supported4cmabovetheﬂoor
by two 8 × 8cm pieces of metal. The time that animals
remainedwithbothpawsonthebarwasmeasured upto90s.
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Figure 1: Time-course of the antinociceptive eﬀect of T. catigua
hydroalcoholic extract (200mgkg−1, p.o) on the hot-plate test in
mice. Results are presented as the mean ± SEM; n = 10–12 animals
per group. ∗P<. 05 signiﬁcantly diﬀerent from PBS-treated group
(ANOVA followed by Newmann-Keuls post-hoc test).
2.8. Statistical Analysis. Results are presented as the
mean ± SEM of 8–10 animals for each experimental group.
Statistical comparisonofthe datawas performed bytwo-way
analysis of variance (ANOVA) followed by Bonferroni’s
post-test, or one-way ANOVA followed by Newman-Keuls’
test. P-values ≤ .05 were considered signiﬁcant.
3.Results
3.1. Trichilia catigua Extract Displays Antinociceptive Actions
on the Hot-Plate Test. The antinociceptive eﬀects of
T. catigua hydroalcoholic extract (200mgkg−1, p.o) were
initially investigated in an acute thermal model of nocicep-
tion in mice. The time-course assessment demonstrated that
T. catigua extract (200mgkg−1) began to show antinoci-
ceptive action in the hot-plate paradigm only 3h after its
oral administration, an eﬀect that lasted up to 6h post-
treatment (Figure 1). In contrast, the treatment of animals
with the Fraction 2 (200mgkg−1, i.p.), the Compound 2, or
cinchonain IIB (20 and 40mgkg−1, i.p.)did not produceany
signiﬁcant antinociceptive eﬀect in this model (results not
shown).
To evaluate some of the mechanisms involved in the
antinociceptive eﬀects of T. catigua extract in the hot-plate
test, diﬀerent groups of mice were pretreated with naloxone
(2.5mgkg−1, s.c.), SCH23390 (15μgkg −1, i.p.), sulpiride
(50mgkg−1, i.p.), prazosin (1mgkg−1, i.p.), bicuculline
(1mgkg−1, i.p.), PCPA (100mgkg−1, i.p.) or SR141716A
(10mgkg−1, i.p.). Only SCH23390 signiﬁcantly prevent the
antinociception caused by T. catigua extract (P = .04). The
values of maximal possible eﬀect (MPE) were calculated
according to [15] and are compiled in Table 1.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Inﬂuence of several drugs on T. catigua hydroalcoholic extract antinociception eﬀect expressed as MPE (%).
Treatment (dose) Antagonist (dose) Site/mechanism of action MPE (%)
Morphine (5mgkg−1, s.c.) PBS — 100
Naloxone (2.5mgkg−1, i.p.) Non-speciﬁc opioid receptor antagonist 0
T. catigua (200mgkg−1, p.o.) PBS — 39 ± 10
Prazosin (1mgkg−1, i.p.) α1-adrenergic receptor antagonist, 38 ± 8
SR141716A (10mgkg−1, i.p.) Cannabinoidreceptor antagonist 45 ± 7
SCH23390 (15μgkg −1, i.p.) D1 receptor antagonist 0
Sulpiride (50mgkg−1, i.p.) D2 receptor antagonist 48 ± 12
Bicuculline (1mgkg−1, i.p.) GABAA receptor antagonist 22 ± 10
Naloxone (2.5mgkg−1, i.p.) Non-speciﬁc opioid receptor antagonist 20 ± 13
PCPA (100mgkg−1, i.p.) Serotonin synthesis inhibitor 48 ± 8
Each group represents the mean ± SEM of 10 animals.
3.2. Antinociceptive Eﬀects of T. catigua Extract on Mechanical
Hypersensitivity Induced by Carrageenan. When assessed in
the mechanical hypersensitivity induced by carrageenan,
T. catigua extract given orally, demonstrated both preventive
and therapeutic antinociceptive actions. In both conditions,
the antinociceptive actions of the extract lasted for up to
24h, whereas those observed for dexamethasone, morphine
and indomethacin (used as positive control drugs), lasted
for 3–5h (Figures 2 and 3). When the preventive schedule
of administration was carried out, the area under the curve
(AUC)revealed a marked antinociceptive eﬀectfor T. catigua
extract (352 ± 38%), which was not signiﬁcantly diﬀer-
e n tf r o mt h a to b t a i n e df o rd e x a m e t h a s o n e( 2 9 1± 41%)
(Figure 2(b)). Furthermore, according to the calculation
of the AUC, the therapeutic regimen of treatment with
T. catigua extract displayedprominentantinociceptiveeﬀects
(294 ± 47%),which were signiﬁcantly higher in comparison
to those observed for the positive control drugs, morphine
(183 ± 20%)andindomethacin (131 ± 37%)(Figure 3(b)).
3.3. Treatment with T. catigua Extract Reduces Abdominal
Constrictions Induced by Acetic Acid. In the writhing
test, either the hydroalcoholic extract from T. catigua
(200mgkg−1, p.o., given 4h prior) or dypirone
(150mgkg−1, p.o., 1h) signiﬁcantly reduced the number
of writhes after acetic acid (0.8%) injection (P = .0002)
(Figure 4). The obtained percentages of inhibition were
33 ± 6a n d9 4 ± 2% for the extract and dypirone,
respectively.
3.4. Evidence for Involvement of Dopaminergic Pathways in
the Actions of T. catigua Extract. Trichilia catigua extract
did not display any direct dopaminergic-like activities, that
is, it did not induce a reduction of body temperature or
catalepsy per se, but it was able to signiﬁcantly modify the
eﬀects of apomorphine and haloperidol. The hypothermia
induced by apomorphine (16mgkg−1, s.c.) was signiﬁcantly
enhanced by the pretreatment with T. catigua hydroalcoholic
extract (200mgkg−1, p.o.; P = .0001), given 4h before
apomorphine injection (Figure 5). In addition, the catalepsy
induced by haloperidol was also signiﬁcantly decreased by
Table 2:Eﬀect ofT. catigua extractonHaloperidol(1mgkg−1,i.p.)-
induced catalepsy
Treatments Catalepsy time (s)
PBS + PBS 1.8 ± 0.8
PBS + Haloperidol 58.4 ± 13.75∗∗∗
PBS + T. catigua (200mgkg−1)2 . 0 ± 0.6
PBS + T. catigua (400mgkg−1)2 . 2 ± 0.6
T. catigua (200mgkg−1) + Haloperidol 31.4 ± 2.4∗,b
T. catigua (400mgkg−1) + Haloperidol 13.3 ± 3.7c,$
Each group represents the mean ± SEM of 10 animals.
∗∗∗P<. 001, ∗P<. 05 compared with PBS; bP<. 001 compared
with Haloperidol; $P<. 001 compared with T. catigua (200mgkg−1)+
Haloperidol.
pretreating mice with T. catigua extract (F(5,45) = 14.74;
P = .0003; Table 2).
4.Discussion
The evaluation of the eﬀects of T. catigua hydroalcoholic
extract on the CNS was initiated by Campos et al. [8].
The authors demonstrated that this plant extract displays
antidepressant-likeeﬀectsintheforcedswimming test(FST),
probably due to activation of the dopaminergic system and,
to a lesser extent, the serotoninergic systems. In the present
study we have provided additional evidence on the activities
of T. catigua extract in the CNS, mainly through interaction
with dopaminergic system.
We have initially assessed the eﬀects of the extract in
three classical nociception models in mice: the hot-plate,
carrageenan-induced hypernociception and the writhing
tests. The ﬁrst is a widely accepted test related to the activa-
tion of central nociceptive pathways. The von Frey paradigm
is usually employed to test analgesic/antiinﬂammatory sub-
stances, but the carrageenan hypersensitivity is also sensitive
to CNS-acting substances. The last test is usually related
to visceral pain, but since the parietal peritoneum receives
somatic innervations, substances with central action are also
eﬀective in this model [16].Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀect of prophylactic treatment with T. catigua
extract (200mgkg−1, p.o.) and dexamethasone (1mgkg−1, i.p.)
on the mechanical hypersensitivity induced by carrageenan
(300μg/50μl/paw, i.pl.) in mice. (a) Time-course of the anti-
hypernociceptive eﬀect; (b) AUC of the anti-hypernociceptive
eﬀect. Results represent the mean ± SEM; n = 6–8 animals per
group. ∗P<. 05 signiﬁcantly diﬀerent from PBS + PBS-treated
mice; #P<. 05 signiﬁcantly diﬀerent from PBS + carrageenan-
treated mice (ANOVA followed by Newmann-Keuls post-hoc test).
In our study, T. catigua extract produced marked, time-
related and long-lasting antinociceptive eﬀect in the hot-
plate model. This result is in accordance with the previous
one found by Vaz et al. [3], showing that Catuama eﬀects
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Figure 3: Eﬀect therapeutic treatment with T. catigua extract
(200mgkg−1, p.o.), morphine (4mgkg−1, s.c.) and indomethacin
(5mgkg−1, i.p.) on the mechanical hypersensitivity induced by
carrageenan(300μg/50μl/paw,i.pl.)inmice.(a)Time-courseofthe
anti-hypernociceptive eﬀect; (b) AUC of the anti-hypernociceptive
eﬀect. Results represent the mean ± SEM; n = 6–8 animals per
group. ∗P<. 05 signiﬁcantly diﬀerent from PBS + PBS-treated
mice; #P<. 05 signiﬁcantly diﬀerent from PBS + carrageenan-
treated mice; aP<. 05 signiﬁcantly diﬀerent from morphine and
indomethacin-treated mice (ANOVA followed by Newmann-Keuls
post-hoc test).
started to decrease after 6 h. In this test, the antinocicep-
tive activities of T. catigua are probably mediated by the
dopaminergic system, and to a lesser extent, the opioid one.
This conclusion is based on data showing that dopamine6 Evidence-Based Complementary and Alternative Medicine
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writhing test in mice. Results are in mean ± SEM; n = 10–12
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mice; #P<. 05 signiﬁcantly diﬀerent from control (PBS followed by
acetic acid injection) treated mice (ANOVAfollowed by Newmann-
Keuls post-hoc test).
D1 receptor antagonist SCH23390 completely inhibited the
extract antinociceptive eﬀect in the hot-plate test, whilst
the opioid antagonist naloxone prevented it only partially.
Of relevance, it had been previously shown that Catuama
preventedthehypersensitivity inducedbyCompleteFreund’s
Adjuvant (CFA) and LPS in the von Frey test, and these
eﬀects were largely reversed by the non-selective dopamine
receptor antagonist haloperidol [4]. The hypothesis that the
antinociceptive eﬀect of T. catigua extract is probably due
to central analgesic rather than antiinﬂammatory activity
is supported by the observation that Catuama, despite its
anti-hypernociceptive eﬀect against the i.pl. administration
of LPS, was not eﬀective in altering the production of the
pro-inﬂammatory mediators IL-1β,T N F α,P G E 2 or LTB4
[4]. Furthermore, T. catigua extract, at the same doses
thatitsigniﬁcantlyreducedcarrageenan-inducedmechanical
hypernociception, did not signiﬁcantly alter the paw edema
formation elicited by carrageenan injection (results not
shown). However, the possible antiinﬂammatory eﬀect of
other extracts prepared from T. catigua cannot be completely
ruled out. In this regard, Barbosa et al. [17]f o u n dt h a t
phospholipase A2 activity was totally inhibited by T. catigua
extract.
Concerning the inhibitory descending pathways impli-
cated in the control of pain, dopamine has not received as
much attention as serotonin and norepinephrine [18]. The
important role exerted by dopaminergic neurotransmission
in modulating pain perception, opioid-induced antinoci-
ception and natural analgesia within supraspinal regions
(includingthebasal ganglia, insula, anterior cingulatecortex,
thalamus and periaqueductal gray) has only been demon-
strated during the last couple of decades [19–21]. It is
generally accepted that D2 receptor agonists elicit antinoci-
ception, while D1 receptor agonists induce pronociceptive
eﬀects[22, 23]. However, this separation remains as a matter
for discussion. A great body of evidence suggests a close
relationship between the opioid and dopaminergic systems
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Figure 5: T. catigua extract (200mgkg−1, p.o.) eﬀect on apo-
morphine (16mgkg−1, s.c.) induced hypothermia. Results are in
mean ± SEM; n = 10–12 animals per group. ∗P<. 05 signiﬁcantly
diﬀerent from PBS-treated group; cP<. 001 signiﬁcantly diﬀerent
from apomorphine-treated group at thesametimeofmeasurement
(two-way ANOVA followed by Newmann-Keuls post-hoc test).
[24–27]. In the striatum, neurones bearing D1 receptors
also express the opioid peptide dynorphin, whereas cells
containing D2-like receptors express enkephalin. There are
studiesshowingthatdeletionofD2 receptors,byi.c.v.admin-
istration of an antisense probe directed against D2,e n h a n c e s
morphine antinociceptiveactions overμ receptors, ina dose-
dependent manner [28]. The involvement of D1 in the
opioid analgesic eﬀect is supported by some studies showing
that periaquedutal gray dopaminergic pathways participate
in supraspinal nociceptive responses after treatment with
opiates [29].
Antidepressants, mainly mixed serotonin and nora-
drenaline reuptake inhibitors (tricyclics and venlafaxine),
are widely prescribed for the treatment of chronic and
neuropathic pain [30–33]. Nevertheless, the dopaminergic
antidepressant, bupropion, has also shown antinociceptive
properties in animal models [34]. The nature and under-
lying mechanisms of antidepressant analgesia is currently
a matter of debate, but there is evidence showing that
antidepressants may induce the release of endogenous
opioids, and that this eﬀect seems to be independent ofEvidence-Based Complementary and Alternative Medicine 7
their antidepressant eﬀect [30, 35]. Besides that, some
authors support the idea that the analgesic eﬀects of antide-
pressants, such as nomifensine and dopaminergic agonists
(amphetamine, apomorphine, bromocriptine), are related
only to the dopaminergic system [22, 36]. Several studies
suggest that the activation of mesolimbic dopamine neurons
arising from the cell bodies of the ventral tegmental area
(VTA) and projecting to the nucleus accumbens plays an
important role in mediating the suppression of tonic pain
[37].
In order to further investigate the action of T. catigua
extract on the dopaminergic system, we evaluated its eﬀect
on the hypothermia induced by apomorphine and also
on haloperidol-induced catalepsy. It has been suggested
that apomorphine-induced hypothermia results from two
eﬀects [38]: the ﬁrst, observed at small doses (until
2mgkg −1) are antagonized by neuroleptics; the second,
induced by high doses (over 10mgkg−1)a r ea n t a g o n i z e d
by antidepressants. In this study, the extract potentiated
apomorphine-induced hypothermia, an action that could
indicate an agonistic eﬀect on the dopaminergic system.
This result was further conﬁrmed by using the catalepsy
test, where the extract was able to prevent the cataleptic
eﬀect of haloperidol in a dose-dependent manner. The
fact that T. catigua extract has stimulating eﬀects upon
the dopaminergic system is in agreement with previous in
vitro results from our laboratory. In this context, Campos
et al. [8] found a signiﬁcant inhibition of dopamine
uptake (IC50 = 35μgml −1), and an increase in dopamine
release (EC50 = 23μgml −1)b yT. catigua extract. It is
important to remark that this is not an amphetamine-
like eﬀect, since the extract doses of 200 and 400mgkg−1
(i.p.) did not signiﬁcantly aﬀect locomotor activity in mice
[8].
Finally, aiming to identify the substance that could be
responsiblefortheactivity ofT. catigua extract,wealsotested
some puriﬁed substances, named Fraction 2, Compound
2 and cinchonain IIB. However, none of them showed
antinociceptive eﬀects when assessed in the hot-plate test
(data not shown). This result, together with the observation
that in the hot-plate the eﬀect of the extract are signiﬁcant
only 3h after the treatment, lasting for up to 6h, led us
to hypothesize that the active substances from T. catigua
extract could be related with some metabolites present in
the plasma. Some analgesic substances, such as tramadol,
morphine and tricyclic antidepressants [39–41], also have
active metabolites. Additional experiments are necessary to
conﬁrm this hypothesis.
In summary, many authors have already shown that
depression and pain are interconnected disorders, both
pathophysiologically and therapeutically [42–44]. In this
context, T. catigua hydroalcoholic extract presented relevant
eﬀects on the CNS, suggesting that the extract and/or active
principles might represent potential therapeutic options for
the treatment of depression and pain-related diseases, by a
mechanism of action likely to be diﬀerent from that of the
clinically available drugs. Consequently, further experiments
are now in progress to investigate and to identify the active
substance(s) involved in these eﬀects.
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